Fuente: FierceBiotech A phase 2 asthma study of Upstream Bio’s TSLP receptor antagonist has hit its primary endpoint. But with only the 12-week regimen achieving a Tezspire-like reduction in the annualized asthma exacerbation rate, the readout fell short of the best-case scenario and left room for rivals to deliver better data.